Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
April 29, 2025 | Market Access, US, access and pricing, agile, efficient, global, solution
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision.
Following Genesis Research Group’s recent expansion of its real-world data analytics capabilities and the appointment of Ki Park as VP, Market Access Strategy & Analytics, the innovative global HEOR, access & pricing and real-world evidence research organization has fully outlined its integrated market access offering.
Genesis Research Group leverages its proprietary RPR stakeholder engagement platform, a network of 3,500+ vetted payers, clinicians, and KOLs across 65 countries, coupled with deep expertise in access, pricing, HEOR, and real-world analytics, to deliver end-to-end solutions that drive commercial success.
Each of the following capabilities can be integrated to boost results or applied independently—helping clients to transform complex challenges throughout the product lifecycle into competitive advantages.
✅ Global strategic advisory
Navigate complex US and global challenges with clarity and confidence. The company’s experts partner with you to develop detailed strategies on product positioning, pricing, and value demonstration – maximizing commercial success through tailored, market-specific solutions.
✅ US data-driven analytics
Navigate the evolving US market landscape with advanced analytical solutions, from contracting strategy and product adoption to LOE analysis, co pay optimization, and IRA impact assessment. This end-to-end approach delivers robust, actionable insights that drive measurable results.
✅ RPR stakeholder insights
Empower strategic access and pricing decisions with RPR, a proprietary stakeholder engagement platform. Gain actionable and pressure-tested insights from 3,500+ vetted payers, clinicians, and KOLs across 65 countries – delivered faster and more robustly than traditional primary research methods.
✅ Analogue and landscape research
Establish strategic clarity through rigorous analogue lookbacks and detailed landscape assessments. Tailored secondary research servoces deliver precise benchmarking on pricing, reimbursement decisions, and HTA outcomes – seamlessly integrated with access and pricing, HEOR, and evidence generation expertise to reduce uncertainty and inform effective decision-making.
✅ A&P Flexible Integrated Teams (FIT)
Benefit from adaptable contracting models tailored to your specific needs, or build an agile, extended partnership with an innovative Access & Pricing FIT (Flexible Integrated Team) engagement for long-term strategic collaboration.
Visit Genesisrg.com to find out more, or contact solutions@genesisrg.com to ask how they can help you overcome your challenges.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright's HEOR Theater presentation 'MFN Pricing: More Fun to Navigate – A European Roadmap to Success,' with potentially...
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice...
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice...
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...
Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to...
Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication
We are pleased to share that The Evidence Base have carried out a 'deep dive' into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights...